TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)

TD Cowen initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report issued on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $44.00 price target on the stock. TD Cowen’s price objective suggests a potential upside of 193.33% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research note on Friday, January 10th. Cantor Fitzgerald started coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Trading Up 1.6 %

PVLA opened at $15.00 on Wednesday. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $22.32. The firm has a market capitalization of $168.30 million, a P/E ratio of -1.24 and a beta of 0.68.

Insiders Place Their Bets

In related news, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now owns 180,671 shares in the company, valued at $2,336,076.03. This trade represents a 2.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 6.39% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.